Breakingviews - Sanofi begins M&A spree with low-risk $3.7 bln bet
LONDON (Reuters Breakingviews) - Sanofi Chief Executive Paul Hudson is starting a potential M&A spree in a relatively safe fashion. The French drugmaker is buying American biotech Principia Biopharma for $3.7 billion, boosting its presence in the lucrative field of diseases in which the immune system attacks the body. Buying an established collaborator reduces risk, while allowing Sanofi to save on royalty payments.
